Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hôpital Necker-Enfants Malades · Université Paris Cité · +11 more institutions
Abstract
Previously, several individuals with X-linked SCID (SCID-X1) were treated by gene therapy to restore the missing IL-2 receptor gamma (IL2RG) gene to CD34+ BM precursor cells using gammaretroviral vectors. While 9 of 10 patients were successfully treated, 4 of the 9 developed T cell leukemia 31-68 months after gene therapy. In 2 of these cases, blast cells contained activating vector insertions near the LIM domain-only 2 (LMO2) proto-oncogene. Here, we report data on the 2 most recent adverse events, which occurred in patients 7 and 10. In patient 10, blast cells contained an integrated vector near LMO2 and a second integrated vector near the proto-oncogene BMI1. In patient 7, blast cells contained an…
Citation impact
- FWCI
- 74.59
- Percentile
- 100%
- References
- 55
Authors
29- SHSalima Hacein‐Bey‐AbinaCorresponding
Hôpital Necker-Enfants Malades, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
- AGAlexandrine Garrigue
Hôpital Necker-Enfants Malades, Inserm, Université Paris Cité
- GPGary P. Wang
University of Pennsylvania
- JSJean Soulier
Délégation Paris 7, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
- ALAnnick Lim
Inserm, Institut Pasteur
Topics & keywords
- Genetic enhancement
- Cancer research
- Insertional mutagenesis
- Severe combined immunodeficiency
- Leukemia
- Biology
- Progenitor cell
- CDKN2A
- Good health and well-being